Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Matched Targeted Therapy”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Not applicableActive Not RecruitingNCT02670525
What this trial is testing

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Who this might be right for
Recurrent, Refractory, or High Risk LeukemiasMatched Targeted Therapy
Dana-Farber Cancer Institute 338
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390852
What this trial is testing

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT02645149
What this trial is testing

Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 216
Testing effectiveness (Phase 2)Active Not RecruitingNCT06400251
What this trial is testing

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)WithdrawnNCT06400264
What this trial is testing

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439331
What this trial is testing

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Not applicableLooking for participantsNCT03452774
What this trial is testing

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Who this might be right for
Cancer, MetastaticCancerCancer of Pancreas+40 more
Massive Bio, Inc. 50,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439227
What this trial is testing

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439279
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT03158389
What this trial is testing

NCT Neuro Master Match - N²M² (NOA-20)

Who this might be right for
Glioblastoma, Adult
University Hospital Heidelberg 228
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439188
What this trial is testing

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Looking for participantsNCT07499271
What this trial is testing

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University 35
Testing effectiveness (Phase 2)Looking for participantsNCT07510828
What this trial is testing

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Beijing Biotech 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06360588
What this trial is testing

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439149
What this trial is testing

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06360575
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390826
What this trial is testing

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439253
What this trial is testing

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Load More Results